A Boom in High-Value M&A and Licensing Deals in the Exosome Field
During the pandemic, the growth of most biopharma businesses had slowed down, except for COVID-19 vaccines and therapies. Yet, exosome-related deals have thrived even under such difficult circumstances, shedding light on the tremendous potential of startups and ground-breaking technologies. Who are the buyers? And who are the rising stars?
Exosome as IVD: M&A
The most significant med-tech application of exosomes is the ExoDx Prostate Test (EPI), developed by Exosome Diagnostics Inc. (Exosome Dx), now part of Bio-Techne Corp. (NASDAQ: TECH).
EPI, the first exosome-based liquid biopsy test to receive FDA breakthrough
Exosome as IVD: M&A
The most significant med-tech application of exosomes is the ExoDx Prostate Test (EPI), developed by Exosome Diagnostics Inc. (Exosome Dx), now part of Bio-Techne Corp. (NASDAQ: TECH).
EPI, the first exosome-based liquid biopsy test to receive FDA breakthrough
GO Prime with only $1.49 now
LATEST
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24